Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HANS H HERFARTH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1538246574
CMS profile
748946
Location
CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$17,266.46

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $15,532.50 3
Travel and Lodging $1,143.70 4
Food and Beverage $515.27 8
Education $74.99 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $12,735.92 13
Celltrion USA Inc. $4,530.54 3

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HANS H HERFARTH

NPI 1538246574 · CMS profile ID 748946

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHAPEL HILL, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538246574?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538246574?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538246574?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
HANS H HERFARTH, NPI 1538246574, CMS profile ID 748946, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1538246574?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $17,266.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celltrion USA Inc. $1,630.0012/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075852449 CMS
Janssen Biotech, Inc. $143.0412/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819904 CMS
Janssen Biotech, Inc. $74.9907/24/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819916 CMS
Celltrion USA Inc. $2,852.5005/20/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075852445 CMS
Celltrion USA Inc. $48.0405/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075852447 CMS
Janssen Biotech, Inc. $40.0003/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819868 CMS
Janssen Biotech, Inc. $11,050.0003/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819745 CMS
Janssen Biotech, Inc. $19.1703/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819544 CMS
Janssen Biotech, Inc. $59.3503/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819678 CMS
Janssen Biotech, Inc. $39.9603/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819823 CMS
Janssen Biotech, Inc. $58.5803/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819456 CMS
Janssen Biotech, Inc. $445.7603/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819475 CMS
Janssen Biotech, Inc. $296.3403/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819670 CMS
Janssen Biotech, Inc. $129.0103/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819884 CMS
Janssen Biotech, Inc. $361.6003/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819912 CMS
Janssen Biotech, Inc. $18.1203/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078819923 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,664.39 10
PY2020 $19,041.44 14
PY2021 $7,950.00 5
PY2022 $5,950.00 3
PY2023 $3,236.00 3
PY2024 $17,266.46 16
PY2025 $13,500.00 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,575.00 2
PY2025 Principal investigator $12,323.55 21
PY2024 Recipient $319,533.00 4
PY2024 Principal investigator $59,545.89 24
PY2023 Principal investigator $224,917.53 43
PY2022 Principal investigator $370,819.65 53
PY2021 Principal investigator $392,748.05 56
PY2020 Principal investigator $481,918.70 51
PY2019 Recipient $4,200.00 1
PY2019 Principal investigator $373,860.96 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

56 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $3,036.80 12/29/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792488561
Principal investigator 1 ABBVIE INC. $1,465.60 12/28/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792488465
Principal investigator 1 Roche Products Limited $2,668.00 12/23/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040417
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 12/22/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EARLY PROOF OF CONCEPT OF TAK-018 FOR THE PREVENTION OF POSTOPERATIVE CROHN'S DISEASE RECURRENCE No dispute reported 06/30/2026 816789131
Principal investigator 1 Genentech, Inc. $4,038.00 12/21/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040453
Principal investigator 1 Roche Products Limited $1,918.00 12/21/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 836040323
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,650.00 12/17/2021 Non-covered Recipient Entity
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
PROSPECTIVE STUDY ON SURGICAL INTERVENTIONS IN COMPLEX FISTULIZING CONDITIONS (CD-CPAF, CD-RVF, CCF) IN THE US, CANADA, AND EU No dispute reported 06/30/2026 816787051
Principal investigator 1 Roche Products Limited $1,513.80 12/14/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040411
Principal investigator 1 Genentech, Inc. $1,190.70 12/09/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040447
Principal investigator 1 ABBVIE INC. $6,649.60 12/02/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792485355
Principal investigator 1 Genentech, Inc. $901.80 11/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040441
Principal investigator 1 Roche Products Limited $1,740.60 11/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040407
Principal investigator 1 Genentech, Inc. $901.80 10/12/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040435
Principal investigator 1 Roche Products Limited $2,802.60 10/12/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040399
Principal investigator 1 ABBVIE INC. $1,350.40 09/30/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792477005
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $124.01 09/27/2021 Non-covered Recipient Entity
Unc Center For Inflammatory Bowel Disease
Phase 2 UC POM study Primary represents induction No dispute reported 06/30/2026 819903367
Principal investigator 1 Janssen Research & Development, LLC $3,901.04 09/24/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787829349
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,600.00 09/21/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EARLY PROOF OF CONCEPT OF TAK-018 FOR THE PREVENTION OF POSTOPERATIVE CROHN'S DISEASE RECURRENCE No dispute reported 06/30/2026 816760635
Principal investigator 1 Genentech, Inc. $982.80 09/14/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040429
Principal investigator 1 Roche Products Limited $2,209.50 09/14/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040393
Principal investigator 1 ABBVIE INC. $2,700.80 08/26/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792472915
Principal investigator 1 Roche Products Limited $1,872.00 08/10/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040389
Principal investigator 1 Roche Products Limited $1,974.60 07/06/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040383
Principal investigator 1 PFIZER INC. $117,349.00 07/05/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS A PROSPECTIVE NATIONAL MULTICENTER COHORT No dispute reported 06/30/2026 832505603
Principal investigator 1 PFIZER INC. $65,720.00 07/05/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS A PROSPECTIVE NATIONAL MULTICENTER COHORT No dispute reported 06/30/2026 832508055
Principal investigator 1 PFIZER INC. $30,000.00 07/05/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS A PROSPECTIVE NATIONAL MULTICENTER COHORT No dispute reported 06/30/2026 832508065
Principal investigator 1 ABBVIE INC. $19,974.00 07/01/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn?s Disease who have failed anti-TNF therapy No dispute reported 06/30/2026 792466403
Principal investigator 1 Roche Products Limited $3,144.00 07/01/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 836040317
Principal investigator 1 ABBVIE INC. $6,649.60 06/28/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792464241
Principal investigator 1 Janssen Research & Development, LLC $4,742.32 06/18/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787829329
Principal investigator 1 Roche Products Limited $4,370.00 06/17/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040377
Principal investigator 1 Genentech, Inc. $1,884.60 06/15/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040423
Principal investigator 1 ABBVIE INC. $2,534.00 06/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792463043
Principal investigator 1 Novo Nordisk Inc $25,464.38 06/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA
Efficacy of GLP-1 receptor agonist therapy in patients with an ileal -pouch anal anastomosis (IPAA) No dispute reported 06/30/2026 811178145
Principal investigator 1 ABBVIE INC. $1,465.60 06/08/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792462623
Principal investigator 1 Roche Products Limited $2,906.10 06/08/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040371
Principal investigator 1 Janssen Research & Development, LLC $91.00 05/24/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787829313
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,670.00 05/12/2021 Non-covered Recipient Entity
THE UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 4 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ENTYVIO (VEDOLIZUMAB IV) IN THE TREATMENT OF CHRONIC POUCHITIS (EARNEST) No dispute reported 06/30/2026 816723351
Principal investigator 1 Roche Products Limited $2,106.00 05/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040365
Principal investigator 1 ABBVIE INC. $6,649.60 04/29/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792450603
Principal investigator 1 Genentech, Inc. $982.80 04/13/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES No dispute reported 06/30/2026 836040305
Principal investigator 1 ABBVIE INC. $1,350.40 03/31/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792440483
Principal investigator 1 Roche Products Limited $9,580.00 03/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040359
Principal investigator 1 Roche Products Limited $2,106.00 03/09/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040353
Principal investigator 1 ABBVIE INC. $1,350.40 03/01/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792426611
Principal investigator 1 Janssen Research & Development, LLC $91.00 02/19/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 3b Multi Center Randomized Blinded Active Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately to Severely Active Crohns Disease No dispute reported 06/30/2026 787829261
Principal investigator 1 Roche Products Limited $5,536.00 02/19/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040347
Principal investigator 1 Roche Products Limited $750.00 02/16/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040341
Principal investigator 1 Roche Products Limited $1,513.80 02/11/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040335
Principal investigator 1 Roche Products Limited $3,255.00 02/04/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM COHORT 1 INDUCTION COHORT II MAINTENANCE No dispute reported 06/30/2026 836040311
Principal investigator 1 ABBVIE INC. $1,350.40 01/25/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohns Disease No dispute reported 06/30/2026 792412111
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 01/20/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EARLY PROOF OF CONCEPT OF TAK-018 FOR THE PREVENTION OF POSTOPERATIVE CROHN'S DISEASE RECURRENCE No dispute reported 06/30/2026 816682363
Principal investigator 1 Janssen Research & Development, LLC $6,895.00 01/15/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 2a Randomized Double blind Active controlled Parallel group Multi Center Proof of concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulc No dispute reported 06/30/2026 787829279
Principal investigator 1 Janssen Research & Development, LLC $600.00 01/15/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHA PEL HILL
A Phase 2a Randomized Double blind Active controlled Parallel group Multi Center Proof of concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulc No dispute reported 06/30/2026 787829297
Principal investigator 1 Roche Products Limited $1,974.60 01/12/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL
CROHN S DISEASE PROGRAM OLE No dispute reported 06/30/2026 836040329
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 01/12/2021 Non-covered Recipient Entity
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EARLY PROOF OF CONCEPT OF TAK-018 FOR THE PREVENTION OF POSTOPERATIVE CROHN'S DISEASE RECURRENCE No dispute reported 06/30/2026 816679643